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Abstract: Despite significant advances in highly active antiretroviral therapy (HAART), the 
prevalence of neuroAIDS remains high. This is mainly attributed to inability of antiretroviral 
therapy (ART) to cross the blood–brain barrier (BBB), thus resulting in insufficient drug 
 concentration within the brain. Therefore, development of an active drug targeting system is 
an attractive strategy to increase the efficacy and delivery of ART to the brain. We report herein 
development of magnetic azidothymidine 5’-triphosphate (AZTTP) liposomal nanoformula-
tion and its ability to transmigrate across an in vitro BBB model by application of an external 
magnetic field. We hypothesize that this magnetically guided nanoformulation can transverse 
the BBB by direct transport or via monocyte-mediated transport. Magnetic AZTTP liposomes 
were prepared using a mixture of phosphatidyl choline and cholesterol. The average size of 
prepared liposomes was about 150 nm with maximum drug and magnetite loading efficiency 
of 54.5% and 45.3%, respectively. Further, magnetic AZTTP liposomes were checked for 
transmigration across an in vitro BBB model using direct or monocyte-mediated transport 
by application of an external magnetic field. The results show that apparent permeability of 
magnetic AZTTP liposomes was 3-fold higher than free AZTTP. Also, the magnetic AZTTP 
liposomes were efficiently taken up by monocytes and these magnetic monocytes showed 
enhanced transendothelial migration compared to normal/non-magnetic monocytes in presence 
of an external magnetic field. Thus, we anticipate that the developed magnetic nanoformulation 
can be used for targeting active nucleotide analog reverse transcriptase inhibitors to the brain 
by application of an external magnetic force and thereby eliminate the brain HIV reservoir 
and help to treat neuroAIDS.
Keywords: AZTTP, magnetic liposomes, HIV-1 infectivity, transendothelial migration, 
blood–brain barrier
Introduction
Human immunodeficiency virus (HIV-1) appears to be harbored in the brain, as 
 indicated by the presence of large quantities of unintegrated viral DNA in the brain 
of HIV-infected individuals.1 The exact mechanism of virus entry into the brain is not 
clearly elucidated; however the resulting infection leads to a number of central nervous 
system (CNS) disorders collectively known as neuroAIDS.2,3 Currently, no specific 
treatment exists for neuroAIDS, which is mainly attributed to the poor penetrability 
of antiretroviral therapy (ART) across the blood–brain barrier (BBB). The selective 
permeability of the BBB is due to the distinct morphology and enzymatic properties 
of endothelial cells that enable them to form complex tight junctions with minimal 
endocytic activity. This provides a physiological barrier that limits the transport of 
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report encapsulation of magnetic nanoparticles bound 
AZTTP (MP-AZTTP) within the liposomes followed by 
transmigration of MP-AZTTP liposomes across the in vitro 
BBB model system in presence of an external magnetic 
field. We hypothesize that MP-AZTTP liposomes can be 
transported across the BBB via direct transport or via 
monocyte-mediated transport, and that by application of an 
external magnetic field results in more effective transmigra-
tion of magnetic liposomes and magnetic monocyte across 
the BBB in neuroAIDS.
Material and methods
Preparation of liposomes loaded  
with MP-AZTTP liposomes
Magnetic nanoparticle synthesis and AZTTP binding to 
nanoparticles were performed according to the procedure 
we previously described.17 In our previous study we deter-
mined the most optimal reaction conditions for production of 
MP-AZTTP. A reaction time of 2 hour with a ratio of 0.2 mg 
AZTTP to 3 mg magnetic nanoparticles (Fe
3
O
4
, magnetite) 
yields magnetic nanoparticles with 35 µg of AZTTP per mg 
of magnetic nanoparticles. Magnetic liposomes were pre-
pared by reverse-phase evaporation method according to the 
procedure described earlier.16 L-α-Soya phosphatidyl choline 
(PC) and cholesterol (CHOL) were obtained from Sigma (St. 
Louis, MO). In a typical optimized procedure, PC and CHOL 
(1.2:1 mole ratio) were dissolved in chloroform, followed 
by evaporation of a solvent in a rotary evaporator resulting 
in formation of dry lipid film. After completely removing 
all solvent traces, the lipid film was rehydrated under con-
stant shaking with 1 mL of 0.9% saline containing 3 mg of 
MP-AZTTP nanoparticles. This resulted in encapsulation 
of MP-AZTTP into the liposomes. The unencapsulated 
magnetic nanoparticles were removed by magnetic decan-
tation using a weak magnet. Fluorescent rhodamine labeled 
 magnetic liposomes (Rho magnetic liposomes) were prepared 
by incorporation of 1 mol% of rhodamine-DHPE (Invitrogen 
Molecular Probes, Oregon, USA) during the formation of 
the lipid film.
Transmission electron microscopic (TEM) 
examination of MP-AZTTP liposomes
The size of the MP-AZTTP liposome was determined 
using negative staining technique of transmission electron 
 microscopy. A drop of magnetoliposome sample was 
placed on a Formvar-coated grid and was allowed to dry. 
The sample was then stained with uranyl acetate dye 
many blood-borne elements such as macromolecules and 
circulating leukocytes to the brain.4 Previous studies report 
that delivery of ART to the brain is limited especially due to 
the physical structure of the BBB, presence of efflux pumps 
and higher expression of metabolizing enzymes, which 
makes BBB an effective barrier against many antiretroviral 
drugs.5 Therefore, in order to increase the efficacy of ART, 
novel approaches to deliver antiretroviral drugs to the brain 
are warranted.
In recent years, advent of nanotechnology has stimulated 
the development of innovative systems for the delivery of 
drugs and diagnostic agents.6 It is now possible to synthesize, 
characterize and specifically tailor the functional properties 
of nanoparticles for various clinical as well as diagnostic 
applications. Additionally, nanoformulations of small drugs 
delivered systemically are more efficacious and less toxic 
than the same drug delivered in free form. This effectiveness 
of nanoparticle based drug delivery systems is attributed 
to their small size, controlled time release of the drug and 
modification of drug pharmacokinetics and biodistribution 
profile.6,7 In this regard, one type of nanoparticle that has 
gained increasing interest is magnetic nanoparticles, which 
mainly consist of nano-sized iron oxide particles (magnetite; 
Fe
3
O
4
 or maghemite; γ-Fe
2
O
3
). The use of magnetic nanopar-
ticles contributes to a precise delivery of drugs to the exact 
site (eg, inflammation, cancer) by application of an external 
magnetic field.8 In cancer chemotherapy magnetically guided 
drug targeting has been attempted in order to increase the 
efficacy and reduce the deleterious side effects.9,10 Previous 
reports have shown successful delivery of anticancer drugs 
bound to magnetic nanoparticles to treat brain carcinomas.11 
Further, magnetic nanoparticles have been used as an imaging 
agent in the brain for diagnostic purposes.12
Previous studies have also attempted to use monocytes/
macrophage based drug carrier for targeted delivery to the 
brain.13,14 Such an approach utilizes the ability of phagocytes 
to cross the BBB and migrate towards inflammatory sites 
via the process known as diapedesis and chemotaxis. Also, 
 studies report that monocytes/macrophages can cross an 
intact BBB under normal physiological condition.15 Like-
wise, Jain et al has reported monocytes/neutrophils medi-
ated delivery of Arg-Gly-Asp (RGD) anchored magnetic 
liposomes to the brain.16 As a first step towards specific drug 
targeting to brain to treat neuroAIDS, we have shown direct 
binding of 3’-azido-3’-deoxythymidine-5’-triphosphate 
(AZTTP, active form of AZT) to magnetic nanoparticles 
and inhibition of HIV-1 replication in peripheral blood 
mononuclear cells (PBMCs).17 In the current study, we 
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(0.5% uranyl acetate). The grid samples were examined using 
a JEOL (Tokyo, Japan) transmission electron microscope 
operating at 80 kV.
MP-AZTTP encapsulation efficiency  
of the liposomes
MP-AZTTP encapsulation efficiency in liposomes was 
 determined by a modif ication of a method reported 
 previously.18 Briefly, unentrapped MP-AZTTP was separated 
from MP-AZTTP liposomes using Sephadex G-50 mini-
 columns. 150 µL of MP-AZTTP liposomal formulation was 
added in 2.0 mL methanol and incubated for 1 min, followed 
by addition of 1.0 mL of water. The particles were sepa-
rated magnetically followed by measuring the absorbance 
of the supernatant at 267 nm using Spectronic Genesys 
Bio10 spectrophotometer. Standard curve of AZTTP in the 
absence and presence of liposomes were used to determine 
the amount of liposome encapsulated AZTTP. The amount 
of encapsulated magnetite was estimated based on ferrous 
ion by using O-phenanthroline method.16 The calibration 
curve was generated with several different amounts of mag-
netite. Another sample of the MP-AZTTP liposomes was 
assayed for phospholipid content by the method of Steward-
Marshall.19 The calibration curve was generated with several 
different amounts of a phospholipid solution.
Anti-HIV efficacy of MP-AZTTP 
liposomes
Magnetic AZTTP liposomes was assessed for anti-HIV 
 activity in an in vitro model system using HIV-infected 
PBMCs. Briefly, PBMCs (1 × 106 cells/mL) were infected 
with HIV-1 IIIB [×4] (NIH AIDS Research and Reference 
Reagent Program Cat# 398) at a concentration of 103.0 
TCID
50
/mL cells for 3 hours as described by the HIV-1 IIIB 
supplier. Cells were washed and cultured in the presence of 
free AZTTP or MP-AZTTP liposomes (1–100 nM AZTTP 
equivalent) once for 7 and 14 days, the culture superna-
tants were quantitated for p24 antigen by RETRO-TEK 
 HIV-1 p24 antigen ELISA kit (Cat#: 0801200, Zeptome-
trix, Buffalo, NY). Untreated HIV infected PBMCs were 
included as a control. The minimum assay detection limit 
for p24 antigen by ELISA is 7.8 pg/mL as provided by the 
manufacturer (Zeptometrix, Buffalo, NY).
In vitro BBB model
The BBB model was established according to the procedure 
described earlier.20 Primary human brain microvascular 
 endothelial cells (BMVEC) and astrocytes were procured 
from Sciencell Research Laboratories, Carlsbad, CA. 
BMVECs were characterized by immunofluorescent method 
with antibodies to von Willebrand factor (VWF/Factor VIII) 
and CD31 (P-CAM). Human astrocytes were characterized 
by immunofluorescent method with antibody to glial fibrillary 
acidic protein. The cultures were also tested for HIV-1, HBV, 
HCV, mycoplasma, bacteria, yeast and fungi. Both the cul-
tures were used for experiments between passages 2 and 8.
The BBB model consisted of 2-compartment wells in a 
culture plate with the upper compartment separated from the 
lower by a cyclopore polyethylene terephthalate membrane 
(Collaborative Biochemical Products, Becton Dickinson, 
San Jose, CA) with a pore diameter of 3 µm. In a 24-well 
cell culture insert (surface area 0.3 cm2), 1 × 105 BMVEC 
were grown to confluency on the upper side while a conflu-
ent layer of human astrocytes were grown on the underside. 
Intactness of the BBB was judged by measuring the transen-
dothelial electrical resistance (TEER) using Millicell ERS 
microelectrodes (Millipore). A mean TEER value of 150 to 
200 ohms/cm2 cell culture insert is consistent with the forma-
tion of the BBB. The BBB model was used for experiments 
atleast 5 days after cell seeding.
Transmigration of MP-AZTTP liposomes 
across the in vitro BBB
All transmigration experiments were conducted on day 6 of 
the BBB culture after membrane integrity was established 
by TEER measurement. Prior to transmigration experiment 
culture media was replaced with buffered Ringer’s solution 
and allowed to equilibrate for 15 min. The basolateral cham-
ber contained 0.9 mL of buffer, whereas the apical chamber 
contained 0.35 mL to ensure that no pressure gradient existed. 
The transmigration experiment was performed in apical to 
basal direction. The apical chamber contained MP-AZTTP 
liposomes (50 µmol AZTTP equivalent) and the culture inserts 
were incubated for 4 hours at 37°C in the presence or absence 
of a magnet placed below the trans-well chamber. After incu-
bation, the buffer from the lower chamber was collected and 
the magnetic liposomes were concentrated by centrifugation 
at 25,000 g for 15 min. AZTTP was extracted from liposome 
by treatment with a mixture of methanol and water (1:1) 
 followed by HPLC analysis to estimate AZTTP concentration. 
The permeability coefficient was calculated according to the 
following formula as previously descried.21
Papp
 
=
dQ
dt × A × C0
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where Papp: apparent permeability (cm/min)
 dQ/dt: amount of MP-AZTTP liposomes accumulation in 
lower (basal) chamber as a function of time (nmol/min)
A: area of transwell (cm2)
 C
0
: initial concentration of MP-AZTTP liposomes added 
in upper (apical) chamber (nmol/mL)
HPLc analysis of AZTTP
HPLC analysis of AZTTP was performed by a modification 
of a method reported earlier.22 HPLC analysis was car-
ried out with a Thermo-Finnigan chromatograph (Thermo 
Electron Corporation, San Jose, California) consisting of a 
SpectraSystem SMC1000 solvent delivery system, vacuum 
membrane degasser, P4000 gradient pumps, AS3000 auto 
sampler, SpectraSystem UV6000LP detector set at 254 nm 
and ChromQuest 4.1 software. A C18 RP Hypersil GOLD 
column (RP5, 250 × 4.6 mm, pore size 5 µm, Thermo Elec-
tron Corporation) was used and the eluting system consisted 
of a 0.2 M ammonium acetate supplemented with 8 mM 
TBAS (pH 7.5) and acetonitrile in volume ratio ammonium 
acetate: acetonitrile of 95:5. The flow-rate was 1.0 mL/min 
at room temperature.
Monocyte uptake studies
Peripheral blood monocytes were isolated from donor leu-
copacks using density gradient centrifugation procedure 
described by us.23 The purity of isolated monocytes was 
assessed by flow cytometry using a fluorochrome-conjugated 
CD14 antibody and the purity was found to be 90%. The 
isolated monocytes were cultured in RPMI medium supple-
mented with 10% fetal bovine serum, penicillin 100 U/mL 
and streptomycin 100 µg/mL, and 2 mM L-glutamine 
(Gibco-BRL, Gaithersburg, MD) in a 6-well plate at cell 
density of 0.8 × 106 cells/mL for 24 hours. The monocyte 
uptake experiment was performed with fluorescent magnetic 
liposomes. The rhodamine labeled magnetic liposomes (Rho 
ML) were added to each test well after dilution in RPMI buf-
fer, about 100 nmol total lipids per 106 monocytes was used 
followed by incubation of culture plate for 2 and 4 hours. 
After incubation, monocytes were washed 3 times with 
phosphate buffer saline (pH 7.4) to remove non-associated 
magnetic liposomes. The monocytes were then visualized 
and images acquired with an Olympus DP70 digital camera 
mounted on a fluorescence microscope with excitation at 
546 nm and emission collection with a long pass filter at 
590 nm (Zeiss, Germany). All images were processed using 
Adobe Photoshop software.
Transendothelial migration of magnetic 
liposome loaded monocytes across the  
in vitro BBB
As mentioned above, all transmigration assays were 
 performed on day 6 of the BBB culture. 1 × 105 mono-
cytes (with or without magnetic liposomes loaded) in 
100 µl transendothelial migration (RPMI 1640 without 
 phenol red + 1% BSA) medium was added to the upper 
chamber of the in vitro BBB system, the chambers were 
then incubated at 37°C, 5% CO
2
. A block magnet of strength 
0.3 Tesla was placed below the artificial BBB chambers. 
Migrated monocytes were counted in the lower chamber 
after 2 and 4 hours incubation. Percent transendothelial 
migration was calculated with respect to the initial total 
number of cells added to the upper chamber. The number 
of cells transmigrated was counted using a hemocytometer. 
Cell viability was assessed by trypan blue staining.
Statistical analysis
All experiments were performed at least three times in 
duplicates. Data are presented as mean ± SE. The anti-HIV 
efficacy of AZTTP (free and liposome) was analyzed using 
a one way ANOVA with the Bonferroni adjustment (signifi-
cance level P  0.005). The transmigration experiment data 
was analyzed using unpaired Student’s t-test. Results were 
considered significant at P  0.05, with a two-tailed test.
Results
characteristics of MP-AZTTP liposomes
In the past decade, magnetic liposomes have attracted 
 significant attention for various biological and medical 
applications.24,25 In this study, magnetic liposomes containing 
AZTTP were prepared by reverse-phase evaporation method 
by encapsulation of AZTTP modified magnetic nanoparticles 
within the core of liposomes. The size and morphology of the 
magnetoliposomes was determined by TEM with the negative 
staining technique using uranyl acetate dye. A typical TEM 
image of a magnetoliposome sample is shown in Figure 1. 
The micrograph clearly shows the occurrence of relatively 
uniform, spherical shaped nanosized particles. The particles 
are well separated and their average size is ∼25 nm. The aver-
age size of magnetic liposomes is about ∼150 nm.
Also, the MP-AZTTP liposomes formed a pellet when 
kept near an external magnet (field strength ∼0.3 Tesla) indi-
cating their susceptibility to an external magnetic field. The 
encapsulation efficiency of MP-AZTTP in liposomes was 
54.5 ± 6 % (n = 6). Magnetite encapsulation ratio per mol of 
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phospholipid was calculated and found to be 11.3 g magnetite 
per mol of phospholipid with percentage encapsulation to 
be about 45.3%.
Inhibition of p24 antigen production  
by MP-AZTTP liposomes
The magnetic AZTTP liposomes were examined for their 
ability to inhibit HIV-1 replication in an in vitro model 
system using HIV-infected PBMCs. After HIV-1 infection 
PBMCs were cultured with either free AZTTP or magnetic 
AZTTP liposomes at concentration from 1 to 100 nM. 
 Culture supernatants were monitored for viral replication 
by measuring p24 antigen levels on day 7 and 14 post 
infection using an ELISA kit. On day 7 a dose-dependent 
decrease in p24 antigen production was observed with treat-
ment of MP-AZTTP liposomes by HIV-1 infected PBMCs 
at 1 nM (9750 ± 875 ng/mL), 10 nM (3000 ± 115 ng/mL, 
P  0.003) and 100 nM (110 ± 20ng/mL, P  0.0005) 
compared to the untreated HIV-1 infected control cultures 
(14290 ± 2945) (Figure 2). Further, the anti-HIV activity of 
free AZTTP (positive control) and MP-AZTTP liposomes 
were found to be comparable at various doses tested on day 7. 
Figure 1 TEM micrograph of magnetic liposomes. The average size of the liposomes 
is ∼150 nm.
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Figure 2 Magnetic AZTTP liposomes inhibit HIV-1 p24 production. PBMcs (1 × 106 cells/mL) obtained from normal subjects were infected with native HIV-1 IIIB (NIH AIDS 
Research and Reference Reagent Program cat# 398) at a concentration of 103.0 TcID50/mL cells for 3 hours and washed 3 times with Hank’s balanced salt solution (GIBcO-
BRL, Grand Island, NY) before being returned to culture with and without free AZTTP or magnetic AZTTP liposomes (1–100 nM) for 7 and 14 days. The culture supernatants 
were quantitated for HIV-1 p24 antigen using a p24 ELISA kit (ZeptoMetrix corporation, Buffalo, NY). The data represent the average of 3 independent experiments and are 
expressed as ng/mL. Statistical analysis was done using one way ANOVA with Bonferroni adjustment.
#comparison between MP-AZTTP liposome and free AZTTP group.
Abbreviations: AZTTP, azidothymidine 5’-triphosphate; MP-AZTTP, magnetic nanoparticles bound AZTTP.
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However, at day 14 the p24 antigen production was found 
to be slightly lower (although not significant, P  0.06) in 
magnetic AZTTP liposomes treated samples compared to 
free AZTTP (10 nM).
Further, we also examined the non-specific cytotoxicity of 
MP-AZTTP liposomes to PBMCs. The results show that MP-
AZTTP liposomes (100 nM) were not cytotoxic to PBMCs 
as evaluated by XTT viability assay (Table 1).
Transmigration of MP-AZTTP liposomes 
across the in vitro BBB in the presence  
of a magnet
We then examined the ability of magnetic AZTTP liposomes 
to migrate across the artificial BBB model system under the 
influence of an external magnetic field. The intactness of the 
in vitro BBB model was established by TEER measurement. 
A mean TEER value of 150 to 200 ohms/cm2 cell culture 
insert is consistent with the formation of the BBB and was 
also reported earlier.26 Figure 3 represents the apparent 
 permeability of AZTTP transported across the in vitro BBB 
as free AZTTP and as magnetic liposomes. The results showed 
that permeability of MP-AZTTP liposomes in the presence 
of a magnet is significantly higher than that of free AZTTP, 
3.64 × 10-3 cm/min as compared to 1.28 × 10-3 cm/min 
respectively (P  0.0001). Further, results show no significant 
effects on the TEER values of the BBB model before and after 
treatment with the MP-AZTTP liposomes (Table 2).
uptake of magnetic liposomes  
by peripheral blood monocytes
Previous studies have attempted to use monocytes/
macrophages as cell based drug delivery carriers.13,14,27–29 In 
this experiment, we evaluated the ability of human monocytes 
to phagocytose magnetic liposomes. We co-cultured human 
monocytes in the presence of rhodamine labeled magnetic 
liposomes (Rho-ML) for 2- and 4-hour time intervals. As 
shown in Figure 4 the rhodamine fluorescence increased 
with incubation time. At 4 hours of incubation, most of 
the fluorescence was associated with monocytes indicating 
that 90% of monocytes had taken up Rho ML.
Table 1 cytotoxicity of AZTTP and MP-AZTTP liposomes
Samples % Cell viability
untreated control PBMcs 100
AZTTP treated PBMcs 95 ± 3.8
MP-AZTTP liposome treated PBMcs 93 ± 5.2
Notes: cytotoxicity was performed using XTT cytotoxicity assay (Sigma Aldrich, 
St. Louis, MO, uSA) using uninfected PBMcs. 100 nM of AZTTP was used for this 
experiment.
Abbreviations: AZTTP, azidothymidine 5’-triphosphate; PBMcs, peripheral blood 
mononuclear cells; MP-AZTTP, magnetic nanoparticles bound AZTTP.
Apparent permeability
MP-AZTTP
liposomes
AZTTP
0.00E+00 1.00E−03 2.00E−03 3.00E−03 4.00E−03 5.00E−03
P < 0.0001
Papp (cm/min)
Figure 3 Transmigration of MP-AZTTP liposomes across the blood–brain barrier (BBB) model. Apparent permeability coefficients (Papp) of MP-AZTTP transport across the 
BBB model as free and in magnetic liposomes. The data represents the mean ± SE of 3 independent experiments and is expressed as cm/min. Statistical analysis was performed 
using unpaired Student’s t-test.
Abbreviations: AZTTP, azidothymidine 5’-triphosphate; MP-AZTTP, magnetic nanoparticles bound AZTTP.
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Transendothelial migration of magnetic 
liposomes loaded monocytes
Previous studies have reported that engulfment of magnetic 
liposomes or magnetic nanoparticles by monocytes provide 
a magnetic property to these cells, which then responds to an 
external magnetic field.16,29 Therefore, we tested the ability of 
magnetic liposome loaded monocytes to transmigrate across 
the artificial BBB system with or without the magnet place 
underneath the transwell for the duration of the experiment. 
Figure 5 represents the number of monocytes transmigrated 
across the in vitro BBB. There were statistically signifi-
cant differences, and on post hoc analysis we found that a 
 significantly greater number of magnetic monocytes in the 
magnet group had transmigrated across the BBB at both 
2 hours and 4 hours compared to the non-magnetic mono-
cyte group (control) 28 ± 2 versus 10 ± 1 (P  0.0001) and 
40 ± 3 versus 15 ± 1 (P  0.001). Further, in the within group 
post-hoc comparisons we found that in the magnetic mono-
cytes with magnet group there were a significantly greater 
number of magnetic monocytes that transmigrated at 4 hours 
than at 2 hours (40 ± 3 versus 28 ± 2, P  0.04). Additionally, 
TEER values were not affected before and after the treatment 
of BBB with magnetic monocytes (Table 2).
Discussion
Although highly active antiretroviral therapy (HAART) has 
greatly reduced the disease severity, thereby improving survival 
and quality of life, still individual patient responses are quite 
variable, and the prevalence of neurological complications 
remains high.30,31 Additionally, nucleoside and nucleotide 
analog reverse transcriptase inhibitors (NRTIs) that are 
 important component of HAART have low intracellular ability 
to convert to active nucleoside 5’-triphosphate (NTP) form due 
to inefficiency of enzyme thymidylate kinase in human cells.32 
This leads to the development of drug resistance, toxicity and 
insufficient effective drug levels in virus target tissue.33,34
Table 2 Transendothelial electrical resistance (TEER) values of 
the in vitro blood–brain barrier model before and after treatment 
with magnetic nanoformulation
 Before treatment After treatment
untreated 190 ± 8.2 189.6 ± 9.0
MP-AZTTP liposomes 186 ± 6.4 184.6 ± 5.1
Magnetic monocytes (2 h) 189.7 ± 8.4 186.67 ± 7.2
Magnetic monocytes (4 h) 186.7 ± 9.4 183.67 ± 8.1
Note: Results are expressed as mean ± SD of three separate values.
Abbreviation: MP-AZTTP, magnetic nanoparticles bound AZTTP.
2 h
4 h
Phase Fluorescence Merge
Figure 4 uptake of magnetic liposomes by human monocytes. Monocytes were co-cultured with rDHPE-magnetic liposomes for 2 and 4 hours and their intracellular localiza-
tion was assessed by fluorescence microscopy (Zeiss, Germany). Engulfed magnetic liposomes can be visualized as red fluorescence located within the cell cytoplasm.
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Recently, nanotechnology-based drug delivery systems 
have shown tremendous potential for delivery of drugs across 
the BBB.35 In this report; we describe a magnetically guided 
delivery system for targeting AZTTP, an active form of AZT 
across the BBB. Delivery of active phosphorylated form of 
NRTIs offers an advantage by bypassing the first step of 
intracellular phosphorylation; however it poses a challenge 
in terms of protecting the NTPs from cellular phosphatases 
and neutralizing the electronegative charge of NTP. Thus, 
developing a magnetic nanocarrier by encapsulation of 
AZTTP within the core of liposome may provide an efficient 
approach for delivery of active NRTIs to the brain. In the 
current study, magnetic AZTTP liposomes were prepared 
successfully using a reverse phase evaporation method. TEM 
examination of sample stained with 0.5% uranyl acetate 
shows the occurrence of the layer surrounding each particle, 
which is attributed to the phospholipid coating (Figure 1). 
The prepared magnetoliposomes were characterized for in 
vitro magnetic susceptibility, percent drug and magnetite 
encapsulation efficiency. The prepared magnetoliposomes 
were found to be responsive to an external magnetic field and 
form a pellet in less than 2 min when kept in front of a magnet 
of strength 0.3 Tesla. The maximum drug and magnetite 
loading achieved was 54.5% and 45.3%, respectively, which 
is comparable to that reported previously where diclofenac 
was encapsulated in magnetic liposomes.16
The anti-HIV activity of magnetic AZTTP liposomes 
were compared with free AZTTP in HIV-1 infected human 
PBMCs cultures (Figure 2). Both free and magnetic AZTTP 
formulations were effective inhibitors of HIV-1 in nanomolar 
concentration range. However, on day 14 post infection p24 
antigen levels were found to be slightly lower (although not 
significant) in magnetic AZTTP liposome treated cultures 
compared to free AZTTP cultures. This observation indicates 
a possible sustained release effect of AZTTP due to higher 
retention time in liposomes. This is in agreement to previ-
ous report where 2’,3’-dideoxycytidine-5’-triphosphate 
was encapsulated in liposomes and it remained stable for 
days.36 Thus, the encapsulation of magnetic AZTTP in 
liposomes would increase their efficacy, biocompatibility, 
and also protect the active NRTIs from degradation by 
 cellular phosphatases. Similarly, previous few studies have 
shown increased drug activity and reduced cytotoxicity of 
5’-triphosphates of NRTI encapsulated within the nanogel 
carriers or erythrocytes.37,38
HAART has considerably reduced HIV disease morbidity 
and mortality; however the associated neuroAIDS continues 
to increase, which is mainly attributed to the inability of 
HAART to cross the BBB in sufficient amounts.39 In addi-
tion, it is reported that under normal circumstance AZTTP 
is unable to cross the BBB.40 We used an established in vitro 
BBB model to evaluate the ability of magnetic AZTTP lipo-
somes to cross the BBB under the influence of an external 
magnetic field. The results obtained show that the apparent 
permeability of magnetic AZTTP liposomes was 3-fold 
higher than free AZTTP (Figure 3). This result indicates that 
transmigration ability of AZTTP across the BBB increased 
significantly on binding to magnetic nanoparticles followed 
by transport under the influence of an external magnetic 
field. Previous studies using magnetoliposomes for cancer 
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Figure 5 Transmigration of monocytes across the in vitro blood–brain barrier (BBB). Magnetic liposome loaded monocytes were added in the upper chamber of the BBB 
model with or without a magnet placed underneath for the duration of experiment. At 2 and 4 hours after plating, migrated monocytes were counted in the lower chamber. 
Results are expressed as mean ± SE of three independent experiments. Statistical significance was determined using unpaired Student’s t-test.
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treatment have shown that administration of magnetic 
adriamycin (ADR) liposomes under an external magnetic 
force produced approximately 4-fold higher maximum 
ADR concentration in the tumor than did administration of 
ADR solution alone.41 More recently, magnetic drug targeting 
has shown success in delivery of anticancer drugs to treat 
brain carcinoma.11 Thus, brain-specific delivery of active 
NRTIs through an effective carrier would provide significant 
therapeutic benefits for treatment of neuroAIDS.
In recent years, several studies have described monocytes/
macrophage-based nanocarrier drug delivery system for 
targeting ART to the brain.13,14 Therefore, we evaluated 
the uptake of rhodamine labeled magnetic liposomes by 
 monocytes. Our results show that the rhodamine fluores-
cence increased with incubation time and at 4 h it was evenly 
 distributed throughout the whole cytoplasm, indicating that 
magnetic liposomes were efficiently taken up by monocytes. 
The phagocytosis of magnetic nanoparticles/liposomes by 
monocytes makes them magnetic cells that respond to an 
external magnetic field.16,29 We then checked the ability of 
monocytes to transmigrate across the in vitro BBB model with 
a magnet placed underneath the trans-well plate. Our results 
indicate that magnetic liposomes loaded monocytes showed 
enhanced migration across the BBB model in response to 
an external magnetic force at 2 and 4 h of incubation. Simi-
larly, Muthana and co-workers have demonstrated increased 
migration of magnetic monocytes across a human endothelial 
cell layer into a tumor spheroid indicating the potential of 
magnetic approach for gene therapies.29 Also, RGD-anchored 
magnetic liposomes have been successfully targeted to brain 
via monocyte/neutrophil-mediated transport.16 Further, in our 
studies no change was observed in the TEER values before 
and after treatment with magnetic nanoformulations, which 
indicates no effect on the integrity of BBB due to transport 
of the formulation across the BBB.
Thus, we envisaged that this magnetic liposomal drug 
delivery could provide a viable approach to overcome the 
problem of poor BBB penetration of several antiretroviral 
agents. Also, the transport of magnetic nanoformulation 
across the BBB occur by two routes, 1) direct delivery of 
magnetic nanoformulation under the influence of an external 
magnetic field and 2) uptake of these nanoformulations by 
circulating monocytes/macrophages which can then traverse 
the BBB.
In our studies on specific drug targeting to the brain to 
eliminate the remaining HIV-1 reservoirs, we have developed 
for the first time magnetic AZTTP liposomes and shown that 
they effectively inhibit HIV-1 replication in in vitro infection 
model. In addition, our result indicates that magnetic AZTTP 
nanoformulation migrates across an established BBB model 
via direct and monocyte mediated transport by application 
of an external magnetic field. Further studies to evaluate the 
drug release kinetics and stability of the developed nano-
formulation are currently pursued in our lab. Therefore, the 
delivery of AZTTP using magnetic liposomes is expected to 
be more therapeutic and may reduce the risk of developing 
drug resistant viral strains and further reduces the clinical 
toxicities associated with the use of high doses of NRTIs.
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